Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0435 plus temozolomide in relapsed small cell lung cancer
CTR20222745Phase 2Active
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Feb 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of HTMC0435 and temozolomide in small cell lung cancer (SCLC) (2 arms), sponsored by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. Primary endpoint: Dose-limiting toxicity and adverse events of HTMC0435 plus temozolomide. Started Feb 2023; status: active.
02
Drugs
HTMC0435temozolomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20222745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222745.